Keywords: CNS drugs, Development time, Regulatory approval, Tufts CSDD

CNS disease therapies take 35% longer to develop than other drugs, says Tufts CSDD

Article | 06 March 2012

Drugs developed to treat central nervous system (CNS) diseases take 35% longer to complete clinical trials and receive regulatory approval compared ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in